propranolol has been researched along with oxandrolone in 15 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (13.33) | 29.6817 |
2010's | 11 (73.33) | 24.3611 |
2020's | 2 (13.33) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Herndon, DN; Pereira, CT | 1 |
Gauglitz, GG; Herndon, DN; Jeschke, MG; Williams, FN | 1 |
Finnerty, CC; Herndon, DN; Radhakrishnan, RS; Rojas, Y | 1 |
Børsheim, E; Diaz, EC; Herndon, DN; Porter, C; Sidossis, LS; Suman, OE | 1 |
Brett, SJ; Griffith, DM; Newman, R; Shepherd, SJ | 1 |
Finnerty, CC; Jeschke, MG; Stanojcic, M | 1 |
Andersen, CR; Capek, KD; Finnerty, CC; Guillory, A; Herndon, DN; Klein, GL; Kline, A; Meyer, WJ; Sousse, LE; Suman, OE; Tompkins, RG; Voigt, CD; Wurzer, P | 1 |
Chao, T; Herndon, DN; Ideker, H; Mlcak, RP; Porter, C; Sidossis, LS; Siopi, A; Suman, OE | 1 |
Amtmann, D; Ayadi, AE; Blears, E; Capek, KD; Cox, R; Finnerty, CC; Foncerrada-Ortega, G; Herndon, D; Hundeshagen, G; Jay, JW; Jennings, K; McMullen, K; Meyer, WJ; Prasai, A; Ross, E; Sommerhalder, C; Sousse, LE; Suman, OE | 1 |
Gus, EI; Jeschke, MG; Shahrokhi, S | 1 |
Auger, C; Jeschke, MG; Knuth, CM | 1 |
9 review(s) available for propranolol and oxandrolone
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The pharmacologic modulation of the hypermetabolic response to burns.
Topics: Adrenergic beta-Antagonists; Anabolic Agents; Burns; Catecholamines; Humans; Hypoglycemic Agents; Insulin; Insulin-Like Growth Factor I; Lipolysis; Oxandrolone; Propranolol | 2005 |
Burns: where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogs?
Topics: Anabolic Agents; Blood Glucose; Burns; Growth Hormone; Humans; Insulin; Insulin Resistance; Insulin-Like Growth Factor I; Oxandrolone; Propranolol | 2011 |
Burns: an update on current pharmacotherapy.
Topics: Adrenergic beta-Antagonists; Anabolic Agents; Animals; Burns; Growth Hormone; Humans; Hypoglycemic Agents; Ketoconazole; Oxandrolone; Propranolol; Testosterone | 2012 |
Effects of pharmacological interventions on muscle protein synthesis and breakdown in recovery from burns.
Topics: Adrenergic beta-Antagonists; Anabolic Agents; Androgens; Body Surface Area; Burns; Human Growth Hormone; Humans; Hypoglycemic Agents; Insulin; Metformin; Muscle Proteins; Muscle, Skeletal; Oxandrolone; Propranolol; Recombinant Proteins; Testosterone; Treatment Outcome | 2015 |
Pharmacological Therapy for the Prevention and Treatment of Weakness After Critical Illness: A Systematic Review.
Topics: Adrenergic beta-Antagonists; Anabolic Agents; Critical Illness; Glutamine; Growth Hormone; Humans; Hyperglycemia; Hypoglycemic Agents; Immunoglobulins, Intravenous; Immunologic Factors; Insulin; Muscle Weakness; Oxandrolone; Polyneuropathies; Propranolol | 2016 |
Anabolic and anticatabolic agents in critical care.
Topics: Adrenergic beta-Antagonists; Anabolic Agents; Critical Care; Critical Illness; Humans; Insulin; Oxandrolone; Propranolol | 2016 |
Anabolic and anticatabolic agents used in burn care: What is known and what is yet to be learned.
Topics: Anabolic Agents; Burns; Clonidine; Growth Hormone-Releasing Hormone; Hormones; Human Growth Hormone; Humans; Hypoglycemic Agents; Inflammation; Insulin; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Metformin; Oxandrolone; Propranolol; Testosterone; Thyroid Hormones | 2020 |
Burn-induced hypermetabolism and skeletal muscle dysfunction.
Topics: Burns; Cachexia; Epigenesis, Genetic; Exercise; Human Growth Hormone; Humans; Insulin; Metformin; Muscle Proteins; Muscle, Skeletal; Muscular Atrophy; Oxandrolone; Propranolol; Protein Biosynthesis; Proteolysis; Sepsis; Signal Transduction; Wound Healing | 2021 |
3 trial(s) available for propranolol and oxandrolone
Article | Year |
---|---|
Reversal of Growth Arrest With the Combined Administration of Oxandrolone and Propranolol in Severely Burned Children.
Topics: Adolescent; Burns; Child; Child, Preschool; Drug Therapy, Combination; Female; Growth; Growth Disorders; Humans; Infant; Male; Oxandrolone; Propranolol; Prospective Studies; Testosterone | 2016 |
Propranolol and Oxandrolone Therapy Accelerated Muscle Recovery in Burned Children.
Topics: Adolescent; Basal Metabolism; Body Composition; Burns; Cardiorespiratory Fitness; Child; Exercise Therapy; Female; Heart Rate; Humans; Male; Muscle Strength; Muscle, Skeletal; Oxandrolone; Oxygen Consumption; Propranolol | 2018 |
Reduced Postburn Hypertrophic Scarring and Improved Physical Recovery With Yearlong Administration of Oxandrolone and Propranolol.
Topics: Adolescent; Anabolic Agents; Biomarkers; Biopsy; Burns; Child; Cicatrix, Hypertrophic; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Immunoenzyme Techniques; Male; Oxandrolone; Propranolol; Prospective Studies; Quality of Life; Recovery of Function; Treatment Outcome; Vasodilator Agents | 2018 |
3 other study(ies) available for propranolol and oxandrolone
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |